Nanobiotix S.A. (NBTX)
NASDAQ: NBTX · Real-Time Price · USD
22.78
+2.27 (11.07%)
At close: Oct 6, 2025, 4:00 PM EDT
21.95
-0.83 (-3.64%)
Pre-market: Oct 7, 2025, 4:38 AM EDT
Nanobiotix Revenue
Nanobiotix had revenue of 26.64M EUR in the half year ending June 30, 2025, with 708.93% growth. This brings the company's revenue in the last twelve months to 10.16M, down -75.93% year-over-year. In the year 2024, Nanobiotix had annual revenue of -7.19M, down -119.86%.
Revenue (ttm)
10.16M EUR
Revenue Growth
-75.93%
P/S Ratio
87.65
Revenue / Employee
94,065 EUR
Employees
108
Market Cap
1.05B USD
Revenue Chart
* This company reports financials in EUR.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | -7.19M | -43.40M | -119.86% |
Dec 31, 2023 | 36.21M | 31.43M | 658.12% |
Dec 31, 2022 | 4.78M | 2.13M | 80.43% |
Dec 31, 2021 | 2.65M | 322.00K | 13.85% |
Dec 31, 2020 | 2.33M | -216.00K | -8.50% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
NBTX News
- 4 days ago - Top 2 Health Care Stocks That May Keep You Up At Night This Month - Benzinga
- 5 days ago - NANOBIOTIX Announces First Data From Phase 1 Study Evaluating JNJ-1900 (NBTXR3) for Patients With Esophageal Cancer - GlobeNewsWire
- 6 days ago - NANOBIOTIX Provides Business Update and Reports Half Year 2025 Financial Results - GlobeNewsWire
- 7 days ago - NANOBIOTIX Announces Updated Phase 1 Results Continuing to Support JNJ-1900 (NBTXR3) Plus Anti-PD-1 as a Potential New 1L or 2L+ Option in Anti-PD-1 Naïve or Resistant R/M-HNSCC - GlobeNewsWire
- 18 days ago - Melanoma Data Study Boosts J&J Partner Nanobiotix Stock On Thursday - Benzinga
- 18 days ago - Nanobiotix: Today's Data Readout For Radiation Therapy Enhances Bull Case - Seeking Alpha
- 18 days ago - Nanobiotix S.A. - Special Call - Seeking Alpha
- 19 days ago - NANOBIOTIX Announces New Results From a Phase 1 Study Evaluating JNJ-1900 (NBTXR3) in Combination With Immune Checkpoint Inhibitors as a 2L+ Therapy for Patients With Primary Cutaneous Melanoma Resistant to Anti-PD-1 - GlobeNewsWire